Suggested remit: To appraise the clinical and cost effectiveness of avacopan within its marketing authorisation for treating anti-neutrophil cytoplasmic antibody-associated vasculitis.
Following on from information provided to NICE by the company in March 2020, the appraisal of Avacopan for inducing remission in anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1178] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1178
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 22 November 2022 | Discontinued. Following on from information provided to NICE by the company in March 2020, the appraisal of Avacopan for inducing remission in anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1178] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 09 March 2020 | Suspended. Topic is suspended |
| 09 March 2020 | Note added to the project documents |
| 14 February 2019 | Note added to the project documents |
| 20 March 2018 - 19 April 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 17 August 2017 | Note added to the project documents |
| 18 July 2017 - 15 August 2017 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual